Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal Cancer.

[1]  O. Larsson,et al.  mTOR coordinates protein synthesis, mitochondrial activity and proliferation , 2015, Cell cycle.

[2]  A. Harris,et al.  Acetyl-CoA Synthetase 2 Promotes Acetate Utilization and Maintains Cancer Cell Growth under Metabolic Stress , 2015, Cancer cell.

[3]  P. Hoff,et al.  Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib , 2014, British Journal of Cancer.

[4]  G. Mazzucchelli,et al.  Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal. , 2014, Cell metabolism.

[5]  P. Hoff,et al.  Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy , 2013, British Journal of Cancer.

[6]  A. Rudich,et al.  Secreted Human Adipose Leptin Decreases Mitochondrial Respiration in HCT116 Colon Cancer Cells , 2013, PloS one.

[7]  R. Swann,et al.  Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy , 2013, Clinical Cancer Research.

[8]  Zhaoshi Jiang,et al.  An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapy , 2013, Nature Medicine.

[9]  Matthew J. Brauer,et al.  Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies , 2013, Clinical Cancer Research.

[10]  J. Koutcher,et al.  Response of HT29 colorectal xenograft model to cediranib assessed with 18F‐fluoromisonidazole positron emission tomography, dynamic contrast‐enhanced and diffusion‐weighted MRI , 2013, NMR in biomedicine.

[11]  Yongzhi Yang,et al.  Obesity and Risk of Colorectal Cancer: A Systematic Review of Prospective Studies , 2013, PloS one.

[12]  Jie Zheng,et al.  Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review). , 2012, Oncology letters.

[13]  Ivana Vucenik,et al.  Annals of the New York Academy of Sciences Obesity and Cancer Risk: Evidence, Mechanisms, and Recommendations , 2022 .

[14]  Ying Cheng,et al.  Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  John V Heymach,et al.  Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. , 2012, The Lancet. Oncology.

[16]  W. Zhang,et al.  Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib) , 2012, The Pharmacogenomics Journal.

[17]  Gregory Stephanopoulos,et al.  Amplification of phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis , 2012, BMC Proceedings.

[18]  S. Barry,et al.  Expression of stromal genes associated with the angiogenic response are not differentiated between human tumour xenografts with divergent vascular morphologies , 2012, Angiogenesis.

[19]  V. Mootha,et al.  Metabolite Profiling Identifies a Key Role for Glycine in Rapid Cancer Cell Proliferation , 2012, Science.

[20]  W. Sly,et al.  Carbonic Anhydrase IX Promotes Tumor Growth and Necrosis In Vivo and Inhibition Enhances Anti-VEGF Therapy , 2012, Clinical Cancer Research.

[21]  Hui Chen,et al.  Leptin regulates proliferation and apoptosis of colorectal carcinoma through PI3K/Akt/mTOR signalling pathway , 2012, Journal of Biosciences.

[22]  C. Punt,et al.  Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy. , 2011, European journal of cancer.

[23]  F. Wacker,et al.  Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy? , 2011, The oncologist.

[24]  A. Harris,et al.  DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. , 2011, Cancer research.

[25]  O. Thews,et al.  Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization. , 2011, Cancer research.

[26]  A. Harris,et al.  Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK787/ZK 222584 (Vatalanib) Antiangiogenic Therapy , 2011, Clinical Cancer Research.

[27]  Zena Wilson,et al.  Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family , 2011, Molecular Cancer Therapeutics.

[28]  J. Christensen,et al.  HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. , 2010, Cancer research.

[29]  S. Chua,et al.  Tumorigenesis and Neoplastic Progression Leptin Receptor Signaling Supports Cancer Cell Metabolism through Suppression of Mitochondrial Respiration in Vivo , 2010 .

[30]  D. Schadendorf,et al.  Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma , 2010, The Journal of Experimental Medicine.

[31]  Franck Bonnetain,et al.  Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer , 2009, Gut.

[32]  Jeffrey W. Clark,et al.  Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. , 2009, Cancer research.

[33]  R. Kerbel,et al.  Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy , 2009, Clinical Cancer Research.

[34]  I. Kasman,et al.  PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. , 2009, Cancer cell.

[35]  L. Ellis,et al.  VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.

[36]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[37]  N. Ferrara,et al.  Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. , 2008, Cancer research.

[38]  Alicja Wolk,et al.  Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. , 2007, The American journal of clinical nutrition.

[39]  G. Fuh,et al.  Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells , 2007, Nature Biotechnology.

[40]  A. Russo,et al.  Expression of the obesity hormone leptin and its receptor correlates with hypoxia-inducible factor-1 alpha in human colorectal cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  E. Surmacz,et al.  Overexpression of the obesity hormone leptin in human colorectal cancer , 2006, Journal of Clinical Pathology.

[42]  E. Surmacz,et al.  Leptin and cancer , 2006, Journal of cellular physiology.

[43]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[44]  S. Barry,et al.  AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. , 2005, Cancer research.

[45]  D. Hanahan,et al.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.

[46]  T. Roskams,et al.  Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer , 2002, International journal of cancer.

[47]  P. Bohlen,et al.  Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy , 2002, International journal of cancer.

[48]  Ju Yong Lee,et al.  Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro , 2001, Experimental & Molecular Medicine.

[49]  R. Busse,et al.  Leptin, the product of Ob gene, promotes angiogenesis. , 1998, Circulation research.

[50]  R. Holman,et al.  UKPDS 20: plasma leptin, obesity, and plasma insulin in type 2 diabetic subjects. , 1997, The Journal of clinical endocrinology and metabolism.

[51]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[52]  이연수.  Functional genomics reveal that the serine synthesis pathway is essential in breast cancer , 2011 .

[53]  Tracy T Batchelor,et al.  Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. , 2011, Cancer research.

[54]  Christian M. Metallo,et al.  Metabolic pathway alterations that support cell proliferation. , 2011, Cold Spring Harbor symposia on quantitative biology.

[55]  Jeffrey W. Clark,et al.  Lessons from phase III clinical trials on anti-VEGF therapy for cancer , 2006, Nature Clinical Practice Oncology.

[56]  In Brief,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .